Investor sentiment around several major stocks got a boost this week thanks to upbeat commentary from Jim Cramer and fresh analyst support.
On CNBC's “Mad Money Lightning Round,” Cramer praised both Lowe’s Companies, Inc. (NYSE:LOW) and CrowdStrike Holdings, Inc. (NASDAQ:CRWD).
“Marvin Ellison [CEO of Lowe’s] is hitting the ball,” Cramer added with a buy recommendation. “He's doing his best.”
Supporting his view, Guggenheim analyst Steven Forbes, on July 22, reiterated Lowe’s Companies with a Buy and maintained a $300 price target.
When asked about CrowdStrike, he said, “Take out your cost basis, and then you're going to let the rest run. And I'll see you at $1000.”
Macquarie analyst Steve Koenig, on July 17, initiated coverage on CrowdStrike with a Neutral rating and announced a price target of $465.
“We're still on the verge of finding out what this Seagen acquisition does,” Cramer said when asked about Pfizer Inc. (NYSE:PFE). “Let's give Dr. Bourla [CEO of Pfizer] two more quarters.”
As per the recent news, Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer alliance, on July 17, announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance's patient resource, Eliquis 360 Support, on Thursday. Eliquis is a blood-thinning medication that reduces blood clotting and prevents strokes.
Price Action:
- Pfizer shares gained 0.9% to settle at $25.36 on Wednesday.
- CrowdStrike shares fell 2.1% to close at $461.52.
- Lowe's shares gained 1.3% to settle at $228.61 on Wednesday.
Image: Shutterstock
